Q2 FY2026 EarningsQ2 FY26 outperformed consensus on the top line, with total revenue reaching $169.6M vs. $157.3M expected, driven by a 96% YoY surge in FILSPARI sales ($141.1M). Despite the revenue beat, GAAP EPS of -$0.37 missed the -$0.16 consensus due to a $40M one-time inducement expense from debt repurchases. Management reported a strong FSGS launch and continued IgAN growth, supported by 2,012 new patient start forms during the quarter.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Travere Therapeutics(TVTX) the Revenue is 169.58 M (+48.17%), Beat estimate;the EBIT is 3.954 M (+131.3%), Beat estimate;the EPS is -0.37 (-164.3%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.17B48.17%
0.16B37.41%
+0.01B10.76%
EBITExceed expectations
0.00B131.26%
-0.02B83.49%
+0.03B214.75%
EPSMiss expectations
-0.37164.29%
-0.158913.49%
-0.2111150.80%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf